George W Booz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7888872/publications.pdf

Version: 2024-02-01

70 papers	2,773 citations	279798 23 h-index	189892 50 g-index
120 all docs	120 docs citations	120 times ranked	5111 citing authors

#	Article	IF	Citations
1	Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiological Reviews, 2018, 98, 1627-1738.	28.8	673
2	Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets. European Journal of Pharmacology, 2018, 820, 65-76.	3.5	219
3	Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radical Biology and Medicine, 2011, 51, 1054-1061.	2.9	180
4	Highâ€fat diet induces cardiac remodelling and dysfunction: assessment of the role played by <scp>SIRT</scp>3 loss. Journal of Cellular and Molecular Medicine, 2015, 19, 1847-1856.	3.6	106
5	Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies. Frontiers in Physiology, 2018, 9, 105.	2.8	102
6	Conflicting vascular and metabolic impact of the IL-33/sST2 axis. Cardiovascular Research, 2018, 114, 1578-1594.	3.8	96
7	Targeting vascular inflammation in ischemic stroke: Recent developments on novel immunomodulatory approaches. European Journal of Pharmacology, 2018, 833, 531-544.	3.5	96
8	An Update on the Multifaceted Roles of STAT3 in the Heart. Frontiers in Cardiovascular Medicine, 2019, 6, 150.	2.4	81
9	Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Failure Reviews, 2018, 23, 419-437.	3.9	79
10	Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology. Frontiers in Bioscience - Landmark, 2016, 21, 1427-1463.	3.0	75
11	Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiological Genomics, 2018, 50, 20-34.	2.3	74
12	CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study. Journal of Cardiovascular Translational Research, 2016, 9, 302-314.	2.4	68
13	Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases. Clinical Science, 2016, 130, 463-478.	4.3	67
14	Pivotal Importance of STAT3 in Protecting the Heart from Acute and Chronic Stress: New Advancement and Unresolved Issues. Frontiers in Cardiovascular Medicine, 2015, 2, 36.	2.4	64
15	The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart. Journal of Immunology Research, 2016, 2016, 1-12.	2.2	61
16	Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. Frontiers in Endocrinology, 2017, 8, 160.	3.5	50
17	Recent Developments on the Crosstalk Between STAT3 and Inflammation in Heart Function and Disease. Frontiers in Immunology, 2018, 9, 3029.	4.8	49
18	IL-33 (Interleukin 33)/sST2 Axis in Hypertension and Heart Failure. Hypertension, 2018, 72, 818-828.	2.7	44

#	Article	IF	Citations
19	Accelerated cerebral vascular injury in diabetes is associated with vascular smooth muscle cell dysfunction. GeroScience, 2020, 42, 547-561.	4.6	41
20	Functional, Cellular, and Molecular Remodeling of the Heart under Influence of Oxidative Cigarette Tobacco Smoke. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-16.	4.0	37
21	Conflicting roles of 20-HETE in hypertension and renal end organ damage. European Journal of Pharmacology, 2018, 833, 190-200.	3.5	37
22	Nicotinamide adenine dinucleotide: Biosynthesis, consumption and therapeutic role in cardiac diseases. Acta Physiologica, 2021, 231, e13551.	3.8	34
23	Conflicting Roles of 20-HETE in Hypertension and Stroke. International Journal of Molecular Sciences, 2019, 20, 4500.	4.1	32
24	Novel Mechanistic Insights and Potential Therapeutic Impact of TRPC6 in Neurovascular Coupling and Ischemic Stroke. International Journal of Molecular Sciences, 2021, 22, 2074.	4.1	32
25	Cerebral blood flow alteration following acute myocardial infarction in mice. Bioscience Reports, 2018, 38, .	2.4	23
26	A Mutation in Î³-Adducin Impairs Autoregulation of Renal Blood Flow and Promotes the Development of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 687-700.	6.1	23
27	STAT3 and Endothelial Cellâ€"Cardiomyocyte Dialog in Cardiac Remodeling. Frontiers in Cardiovascular Medicine, 2019, 6, 50.	2.4	21
28	Hydrogels as a Platform for Stem Cell Delivery to the Heart. Congestive Heart Failure, 2010, 16, 132-135.	2.0	20
29	Recent Insights Into the Protective Mechanisms of Paeoniflorin in Neurological, Cardiovascular, and Renal Diseases. Journal of Cardiovascular Pharmacology, 2021, 77, 728-734.	1.9	20
30	The Role of Mitochondrial Dysfunction in Preeclampsia: Causative Factor or Collateral Damage?. American Journal of Hypertension, 2021, 34, 442-452.	2.0	19
31	Applying Fractal Dimension and Image Analysis to Quantify Fibrotic Collagen Deposition and Organization in the Normal and Hypertensive Heart. Microscopy and Microanalysis, 2014, 20, 1134-1144.	0.4	18
32	Temporal cardiac remodeling post-myocardial infarction: dynamics and prognostic implications in personalized medicine. Heart Failure Reviews, 2016, 21, 25-47.	3.9	18
33	Cardiac STAT3 Deficiency Impairs Contractility and Metabolic Homeostasis in Hypertension. Frontiers in Pharmacology, 2016, 7, 436.	3.5	17
34	Impact of the Reninâ€"Angiotensin System on the Endothelium in Vascular Dementia: Unresolved Issues and Future Perspectives. International Journal of Molecular Sciences, 2020, 21, 4268.	4.1	16
35	IL-33 induces type-2-cytokine phenotype but exacerbates cardiac remodeling post-myocardial infarction with eosinophil recruitment, worsened systolic dysfunction, and ventricular wall rupture. Clinical Science, 2020, 134, 1191-1218.	4.3	15
36	Role of ranolazine in heart failure: From cellular to clinic perspective. European Journal of Pharmacology, 2022, 919, 174787.	3.5	14

#	Article	IF	Citations
37	Critical appraisal of STAT3 pattern in adult cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2019, 131, 91-100.	1.9	11
38	Cardioprotective Effects of the Novel Compound Vastiras in a Preclinical Model of End-Organ Damage. Hypertension, 2020, 75, 1195-1204.	2.7	11
39	Aging diabetes, deconstructing the cerebrovascular wall. Aging, 2021, 13, 9158-9159.	3.1	11
40	Early cardiac-chamber-specific fingerprints in heart failure with preserved ejection fraction detected by FTIR and Raman spectroscopic techniques. Scientific Reports, 2022, 12, 3440.	3.3	11
41	Angiotensin II type 1 receptor agonistic autoantibody blockade improves postpartum hypertension and cardiac mitochondrial function in rat model of preeclampsia. Biology of Sex Differences, 2021, 12, 58.	4.1	9
42	Angiotensin II type 1 receptor autoantibody blockade improves cerebral blood flow autoregulation and hypertension in a preclinical model of preeclampsia. Hypertension in Pregnancy, 2020, 39, 451-460.	1.1	7
43	Interferon Î³ neutralization reduces blood pressure, uterine artery resistance index, and placental oxidative stress in placental ischemic rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2021, 321, R112-R124.	1.8	7
44	Insights into the modulation of the interferon response and NAD+ in the context of COVID-19. International Reviews of Immunology, 2021, , 1-11.	3.3	7
45	Carvedilol protects the infarcted heart by upregulating miR-133: First evidence that disease state affects Î²-adrenergic arrestin-biased signaling?. Journal of Molecular and Cellular Cardiology, 2014, 76, 12-14.	1.9	6
46	Deleting Vascular ADAM17 Sheds New Light on Hypertensive Cardiac Hypertrophy. Hypertension, 2016, 68, 849-850.	2.7	6
47	In Silico Analysis of Differential Gene Expression in Three Common Rat Models of Diastolic Dysfunction. Frontiers in Cardiovascular Medicine, 2018, 5, 11.	2.4	6
48	Untangling the Interplay Between Mitochondrial Fission and NF-ÎºB Signaling in Endothelial Inflammation. Hypertension, 2020, 76, 23-25.	2.7	6
49	Atrial Natriuretic Peptide31â€“67: A Novel Therapeutic Factor for Cardiovascular Diseases. Frontiers in Physiology, 2021, 12, 691407.	2.8	6
50	Sex-based differences in myocardial infarction-induced kidney damage following cigarette smoking exposure: more renal protection in premenopausal female mice. Bioscience Reports, 2020, 40, .	2.4	5
51	What Role do Mitochondria Have in Diastolic Dysfunction? Implications for Diabetic Cardiomyopathy and Heart Failure With Preserved Ejection Function. Journal of Cardiovascular Pharmacology, 2022, 79, 399-406.	1.9	5
52	Sex differences in cardiac remodeling post myocardial infarction with acute cigarette smoking. Biology of Sex Differences, 2022, 13, .	4.1	5
53	Editorial: Cardiac Microvascular Endothelium Contribution to Cardiac Myocyte Growth, Structure, and Contractile Function. Frontiers in Cardiovascular Medicine, 2019, 6, 130.	2.4	4
54	Spatiotemporal Dynamics of Immune Cells in Early Left Ventricular Remodeling After Acute Myocardial Infarction in Mice. Journal of Cardiovascular Pharmacology, 2020, 75, 112-122.	1.9	4

#	Article	IF	Citations
55	Genderâ€biased kidney damage in mice following exposure to tobacco cigarette smoke: More protection in premenopausal females. Physiological Reports, 2020, 8, e14339.	1.7	4
56	Levosimendan Comes of Age: 20 Years of Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 1-3.	1.9	4
57	Targeting mitochondria to protect the heart: a matter of balance?. Clinical Science, 2020, 134, 885-888.	4.3	4
58	The Angiotensin II Type 1(AT1) Receptor and Cardiac Hypertrophy: Did We Have It Wrong All Along?. Journal of Cardiovascular Pharmacology, 2021, 77, 531-535.	1.9	3
59	Unravelling the impact of intrauterine growth restriction on heart development: insights into mitochondria and sexual dimorphism from a non-hominoid primate. Clinical Science, 2021, 135, 1767-1772.	4.3	3
60	Conflicting mechanisms of AT2 cardioprotection revealed. Cardiovascular Research, 2016, 112, 426-428.	3.8	2
61	Editorial: Immunomodulatory Approaches in Cardiovascular Diseases. Frontiers in Cardiovascular Medicine, 2022, 9, 873452.	2.4	2
62	A Few Initial Thoughts on Receiving the Baton. Journal of Cardiovascular Pharmacology, 2018, 72, 2.	1.9	1
63	Cardiovascular Pharmacology of the NLRP3 Inflammasome. Journal of Cardiovascular Pharmacology, 2019, 74, 173-174.	1.9	1
64	Science unites a troubled world: Lessons from the pandemic. European Journal of Pharmacology, 2021, 890, 173696.	3.5	1
65	Seizing the Future: What's Next for the Journal of Cardiovascular Pharmacology?. Journal of Cardiovascular Pharmacology, 2019, 73, 1-2.	1.9	0
66	Deciphering the Dynamics and Therapeutic Potential of the Cardiac cGMP Cascade: An Update on Where We Are and What We Need to Know. Journal of Cardiovascular Pharmacology, 2020, 75, 368-369.	1.9	0
67	Distorted assessment of left atrial size by echocardiography in patients with increased aortic root diameter. Egyptian Heart Journal, 2021, 73, 55.	1.2	0
68	Transient Receptor Potential Type C Channels Play a Critical Role in Angiogenesis. FASEB Journal, 2011, 25, 1091.12.	0.5	0
69	Hypertensionâ€Induced Renal Injury is Associated with Impaired Glomerular Barrier Function Involving Podocyte Dysfunction. FASEB Journal, 2019, 33, 573.9.	0.5	0
70	Angiotensin II Type I Receptor Agonistic Autoantibody Blockade Improves Cerebral Blood Flow Autoregulation, Blood Brain Barrier Permeability, and Hypertension in the Preâ€Clinical Rat Model of Preeclampsia. FASEB Journal, 2020, 34, 1-1.	0.5	0